Startups
2014
IMIDOMICS SLCRITICAL INSIGHTS FOR TREATING PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES
IMID patient biobank and clinical data repository of the highest quality
IMID patient biobank and clinical data repository of the highest quality
Address
Carrer de Baldiri Reixac 4-8, 08028 Barcelona, Spain
Finance Data
CERCA ownership
Barcelona, Spain
2002
Vall d’Hebron Institut de Recerca (VHIR)
Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
Our Vision: to drive changes to traditional drug discovery and treatment strategies by employing state-of-the-art methods and technologies to deeply understand patients and their underlying conditions
Our Mission: to partner with Pharma, Health companies, Payers, Big Data and Physicians to develop precision medicine diagnostics and new therapeutics that optimize treatment of IMID patients
Our Mission: to partner with Pharma, Health companies, Payers, Big Data and Physicians to develop precision medicine diagnostics and new therapeutics that optimize treatment of IMID patients
Product description
IMID PATIENTS
Immune-mediated inflammatory disease (IMID) is a concept to describe a group of chronic disorders characterized by the activation of multiple immune and inflammatory pathways. Although each IMID targets different tissues and organs, they all share common clinical features and molecular mechanisms. Their etiology is unknown although genetic and environmental factors are crucial determinants of susceptibility. The estimated prevalence of IMIDs is 7–10% in the general population. IMIDs are associated with a high socio-economic impact and are among the main causes of morbidity, disability, and mortality in developed countries
IMID BIOBANK
IMIDomics has access to the IMID-Biobank, a dynamic, high-quality ISO certified biobank ensures the availability of high-quality biological products to be analyzed using cutting-edge technologies
MULTIOMICS
At IMIDomics we are convinced that only through the integration of data from multiple omic approaches, together with reliable clinical data, that precision medicine will be delivered to IMID patients
PORTAL
IMIDomics portal provides seamless access the biological insights generated through the use of different omic technologies on IMID patients
Immune-mediated inflammatory disease (IMID) is a concept to describe a group of chronic disorders characterized by the activation of multiple immune and inflammatory pathways. Although each IMID targets different tissues and organs, they all share common clinical features and molecular mechanisms. Their etiology is unknown although genetic and environmental factors are crucial determinants of susceptibility. The estimated prevalence of IMIDs is 7–10% in the general population. IMIDs are associated with a high socio-economic impact and are among the main causes of morbidity, disability, and mortality in developed countries
IMID BIOBANK
IMIDomics has access to the IMID-Biobank, a dynamic, high-quality ISO certified biobank ensures the availability of high-quality biological products to be analyzed using cutting-edge technologies
MULTIOMICS
At IMIDomics we are convinced that only through the integration of data from multiple omic approaches, together with reliable clinical data, that precision medicine will be delivered to IMID patients
PORTAL
IMIDomics portal provides seamless access the biological insights generated through the use of different omic technologies on IMID patients
Temporary Data
Temp KTT